Search results for Inebilizumab
Inebilizumab Biosimilar – Anti-CD19 mAb – Research Grade, ProteoGenix, PX-TA1385
Description of Inebilizumab Biosimilar - Anti-CD19 mAb - Research Grade General information on Anti-CD19[Homo sapiens] (Inebilizumab) Monoclonal Antibody Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion.
Host
Reactivity
Applications
Conjugation
Inebilizumab, Abbexa, abx831345
Inebilizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD19, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Inebilizumab Biosimilar - Research Grade, ichor.bio, ICH5168
Detects human CD19
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Research Grade Inebilizumab (HB996026), abinScience, HB996026
Host
Humanized
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.